Eli Lilly and Company today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly’s Oncology business on January 1, 2017.
Dr. Garraway will succeed Richard Gaynor, M.D., who will retire after a distinguished career at Lilly.
Dr. Garraway is currently associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate physician at the Brigham and Women’s Hospital, an Institute Member of the Broad Institute of MIT and Harvard, and an investigator of the Howard Hughes Medical Institute. He will report to Sue Mahony, Ph.D., Lilly senior vice president and president of Lilly Oncology. “We are pleased and honored to have Dr. Garraway join us at Lilly,” Mahony said. “He has made a tremendous impact in his career and is recognized around the world as a leader in oncology.
“We know he will provide keen insight and expertise—and will continue to advance Lilly’s work in developing innovative new medicines to truly make life better for people with cancer around the world.”
Mahony praised Dr. Gaynor for his significant contributions to the discovery and development of cancer medicines. “Richard is known for scientific rigor and deep expertise in drug development, coupled with a personal warmth and care for patients that is truly inspiring,” she said. “He is leaving a remarkable legacy at Lilly through his impact on the pipeline, people and patients.”
About Levi Garraway, M.D., Ph.D.
A graduate of Harvard Medical School, Garraway is director of the Joint Center for Cancer Precision Medicine, which spans Harvard teaching hospitals: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard. He is also co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center.
In addition to his work at Harvard, Dr. Garraway is on the boards of major cancer centers, including Sloan Kettering, MD Anderson and Ohio State, and he is chairman of several major National Institutes of Health (NIH) committees. He also serves on the American Association for Cancer Research (AACR) board of directors and was elected president of the American Society of Clinical Investigation–one of the highest honors for academic clinician scientists.
He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from AACR, the New Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute.
Dr. Garraway’s industry activities also include being a founder of Foundation Medicine, a leading company in cancer genomics diagnostics.
Source: Eli Lilly and Company
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.